The DOI matches its OpenAlex record; 76 of the 76 references it cites were found in a registry or an index.
HIF hydroxylation and the mammalian oxygen-sensing pathway
Open accessAbstract
Hypoxia refers to below-normal levels of oxygen in air, blood, or tissue.Tissue hypoxia leads to cellular dysfunction and ultimately can lead to cell death.Causes of tissue hypoxia include (a) decreased blood oxygenation (such as occurs in certain pulmonary disorders), (b) altered oxygen release from hemoglobin (associated with some hemoglobinopathies), and (c) impaired blood delivery leading to localized anemia (i.e., ischemia) as a result of low cardiac output or vascular obstruction.In order to adapt to hypoxia, mammals use a number of physiological responses.These include (a) increased production of erythropoietin (EPO), which augments the production of red blood cells; (b) induction of tyrosine hydroxylase, which facilitates the control of ventilation through the carotid body; and (c) the stimulation of new blood vessels by upregulation of VEGF (1).At the cellular level, hypoxia induces a number of metabolic changes that allow for continued energy generation despite decreased oxygen availability. Hypoxia-inducible factorOne of the most important factors in the cellular response to hypoxia is hypoxia-inducible factor (HIF), which transcriptionally activates genes encoding proteins that mediate adaptive responses to reduced oxygen availability.HIF is a heterodimer consisting of one of three α subunits (HIF1-α, HIF2-α, or HIF3-α) bound to the aryl hydrocarbon receptor nuclear translocator (ARNT), which is also known as HIF1-β.HIF-α is a member of the basic helix-loop-helix (bHLH) superfamily, in which the HLH domain mediates sub-unit dimerization while the basic domain binds to DNA.HIF-α, like some other bHLH family members, contains a Per/Arnt/Sim (PAS) domain that facilitates the heterodimerization of HIF-α with ARNT (2-4).HIF target genes play critical roles in metabolism, angiogenesis, cell proliferation, and cell survival.Examples of HIF target genes include VEGF, glucose transporter 1 (GLUT1), and EPO.HIF binds to the hypoxia-responsive element, which contains the core recognition sequence 5′-TACGTG-3′ (5), in the cis-regulatory regions of hypoxia-inducible genes.Transcriptional activation by HIF is linked to its ability to recruit coactivator proteins such as CREB-binding protein (CBP), p300, steroid receptor coactivator-1, and translation initiation factor 2 (6-8).Whereas changes in oxygen levels do not affect ARNT protein levels, hypoxia markedly increases the abundance of the HIF-α subunits (9-11).This increase is due primarily to protein stabilization.In some settings, hypoxia also leads to increased HIF1-α mRNA accumulation (12, 13).von Hippel-Lindau disease von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that affects approximately 1 in 35,000 individuals.The syndrome was first described in 1894 by Collins, who observed two siblings with bilateral retinal angiomas (now also called hemangioblastomas) ( 14).Later, the disease was mapped to chromosome 3p25 (15), and the VHL gene itself was isolated in 1993 (16).VHL behaves as a classical tumor suppressor gene.Almost all individuals with a clinical diagnosis of VHL disease can be shown to harbor a germline mutation of the VHL gene, with tumor development linked to somatic inactivation or loss of the remaining wild-type allele (17).The cardinal features of VHL disease are blood vessel tumors of the retina and central nervous system.Other tumors associated with VHL disease include clear cell carcinomas of the kidney, pheochromocytoma, endolymphatic sac tumors, pancreatic islet cell tumors, and papillary cystadenomas of the epididymis (in males) or broad ligament (in females) (18).In addition, patients with VHL often develop multiple visceral cysts involving organs such as the pancreas and kidneys (18).Biallelic VHL inactivation also occurs commonly in patients with sporadic hemangioblastoma or renal cell carcinoma,
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Research works printed but not linked: 9
- Collins, 1894, Trans. Ophthalmol. Soc. U. K., 14, 141
- Shuin, 1994, Cancer Res., 54, 2852
- Whaley, 1994, Am. J. Hum. Genet., 55, 1092
- Kanno, 1994, Cancer Res., 54, 4845
- Siemeister, 1996, Cancer Res., 56, 2299
- Kishida, 1995, Cancer Res., 55, 4544
- Yu, 2001, Cancer Res., 61, 4136
- Drevs, 2000, Cancer Res., 60, 4819
- Yang, 2002, Proc. Am. Soc. Clin. Oncol., 21, 15
Cited by
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
“This sug-mimetic compound (Safran and Kaelin, 2003), for 3 hr. Hypoxia geststhat SDHactivityin transfectedcellsis severelydiminished or hypoxic mimetic treatment induced higher levels of HIF-1 (cid:1) at the time of analysis.”
BackgroundMethod
Metadata
- Authors
- Safran, M., & Kaelin, W. G.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-03-15
- Volume
- 111
- Issue
- 6
- Pages
- 779-783
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2047816152
- Cited by
- 363
- References
- 76
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIF hydroxylation and the mammalian oxygen-sensing pathway. https://app.cochat.ai/papers/10.1172/jci18181
- The paper
- Safran, M., & Kaelin, W. G. (2003). HIF hydroxylation and the mammalian oxygen-sensing pathway. Journal of Clinical Investigation. https://doi.org/10.1172/jci18181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.